Biopharma buyers continue to shift deal-making spending away from M&A
Strategic partnerships rather than M&A will be key for biopharma companies in 2022, finds a report from EY.
Archives for January 10, 2022
AstraZeneca and Neurimmune to develop investigational human monoclonal antibody NI006
Alexion, AstraZeneca’s Rare Disease group, has entered into an exclusive global collaboration and licence agreement with Neurimmune AG for NI006, an investigational human monoclonal antibody currently in Phase Ib development for the treatment of...
Bayer and Mammoth Biosciences collaborate on novel gene editing tech
Bayer AG and Mammoth Biosciences, Inc., have announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.
Novo Holdings acquires blow-fill-seal manufacturing specialist Ritedose
Life science investor group, Novo Holdings, has agreed to buy Ritedose, the largest sterile CDMO in the US focused on advanced blow-fill-seal technology, from Hong-Kong based, AGIC Capital, and China’s Humanwell.